Lexicon Pharmaceuticals Inc expected to post a loss of 10 cents a share - Earnings Preview

Lexicon Pharmaceuticals

28/04/2025 22:02

Lexicon Pharmaceuticals Inc LXRX.OQ LXRX.O is expected to show a rise in quarterly revenue when it reports  results on April 30 (estimated) for the period ending March 31 2025

The The Woodlands Texas-based  company is expected to report a 25.0% increase in revenue to $1.413 million from $1.13 million a year ago, according to the mean estimate from 4 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Lexicon Pharmaceuticals Inc is for a loss of 10 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Lexicon Pharmaceuticals Inc is $1.20​, above​ its last closing price of $0.71. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.13
-0.13
-0.09
Beat
29.3
Sep. 30 2024
-0.17
-0.16
-0.18
Missed
-9.4
Jun. 30 2024
-0.19
-0.19
-0.17
Beat
9.9​
Mar. 31 2024
-0.20
-0.20
-0.20
Met
-1.3
​​Dec. 31 2023
-0.22
-0.22
-0.20
Beat
7.9
Sep. 30 2023
-0.21
-0.21
-0.21
Met
2.2​
Jun. 30 2023
-0.17
-0.17
-0.22
Missed
-25.9
Mar. 31 2023
-0.18
-0.18
-0.17
Beat
5.2

This summary was machine generated April 28 at 21:02 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)